Ingersoll Rand (IR) Q3 2025 Earnings
Reported Oct 30, 2025 at 4:42 PM ET · SEC Source
Q3 25 EPS
$0.86
MISS 0.30%
Est. $0.86
Q3 25 Revenue
$1.96B
BEAT +0.36%
Est. $1.95B
vs S&P Since Q3 25
-1.6%
TRAILING MARKET
IR +7.8% vs S&P +9.3%
Market Reaction
Did IR Beat Earnings? Q3 2025 Results
Ingersoll Rand posted a mixed third quarter, nudging past revenue expectations while falling just short on the bottom line, as acquisition-driven growth papered over underlying organic softness. The industrial manufacturer reported revenue of $1.96 b… Read more Ingersoll Rand posted a mixed third quarter, nudging past revenue expectations while falling just short on the bottom line, as acquisition-driven growth papered over underlying organic softness. The industrial manufacturer reported revenue of $1.96 billion, up 5.0% year-over-year and marginally ahead of the $1.95 billion consensus, but adjusted diluted EPS of $0.86 missed the $0.86 estimate by 0.30%. The story behind the numbers was one of competing forces: M&A contributions of 4.7% and a 1.6% currency tailwind more than offset a 1.3% organic revenue decline, while tariff-related headwinds and continued commercial investments compressed adjusted EBITDA margin by 70 basis points to 27.9%. A bright spot emerged in orders, which grew 8% to $1.94 billion, suggesting demand conditions are gradually improving. Looking ahead, management set full-year 2025 adjusted EPS guidance of $3.25 to $3.31, with total revenue growth of 4% to 6%, even as the organic revenue outlook for both segments sits at negative 2% to flat, reflecting continued near-term caution. The company recently added to its acquisition pipeline with the purchase of U.K.-based ejector solutions provider Transvac Systems, broadening its Industrial Technologies and Services portfolio.
Key Takeaways
- • IRX (Ingersoll Rand Execution Excellence) operating system driving strong performance
- • Positive organic orders growth across both segments for Q3
- • IT&S delivered third consecutive quarter of organic orders growth
- • P&ST organic orders growth in both Precision Technologies and Life Sciences businesses
- • Acquisitions contributed 4.7% to total revenue growth
- • FX contributed 1.6% to revenue growth
IR YoY Financials
Q3 2025 vs Q3 2024, source: SEC Filings
IR Revenue by Segment
With YoY comparisons, source: SEC Filings
“We delivered positive organic orders growth in the third quarter across both segments. Our performance demonstrates the resilience of our business, which combined with our strong balance sheet, enables durable long-term growth. We remain well positioned for future growth with our proven agile business model, operational excellence, and ownership mindset.”
— Vicente Reynal, Q3 2025 Earnings Press Release
IR Earnings Trends
IR vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
IR EPS Trend
Earnings per share: estimate vs actual
IR Revenue Trend
Quarterly revenue: estimate vs actual
IR Quarterly Results
4 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 BEAT | $0.74 | $0.77 | +4.03% | $1.85B | +0.92% |
| Q4 25 BEAT FY | $0.90 | $0.96 | +6.57% | $2.09B | +2.58% |
| FY Full Year | — | $3.34 | — | $7.65B | — |
| Q3 25 MISS | $0.86 | $0.86 | -0.30% | $1.96B | +0.36% |
| Q2 25 BEAT | $0.80 | $0.80 | +0.40% | $1.89B | +2.21% |